Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
ACCESSWIRE
The addressable market in Canada is estimated to be $80M CDN by 2022.
Tetra also applies for a Health Canada Cannabis Drug License
OTTAWA, ON / ACCESSWIRE / May 3, 2021 /
Tetra Bio-Pharma Inc. ('Tetra' or the
'Company')(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the Company has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft gel capsules in Canada. REDUVO is a synthetic THC-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy and is currently being assessed by Health Canada for the issuance of a Drug Identification Number (DIN). REDUVO, known as Marinol in the United States, has been approved as a regulated pharmaceutical drug by the U.S. Food and Drug Administration since 1985.

Related Keywords

United States ,Canada ,Ottawa ,Ontario ,Canadian ,Natalie Leroux ,Tetra Bio Pharma Inc ,Contract Manufacturing Organization ,Health Canada Cannabis Drug ,Drug Administration ,Health Canada Drug Establishment License ,Health Canada ,Regulation Services Provider ,Health Canada Cannabis Drug License ,Tetra Bio Pharma ,Drug Identification Number ,United States Wire Group ,ஒன்றுபட்டது மாநிலங்களில் ,கனடா ,ஆடவா ,ஆஂடேரியொ ,கனடியன் ,நடாலி லேரௌுக்ஷ ,டெட்ரா உயிர் பார்மா இன்க் ,ஒப்பந்த உற்பத்தி ஆர்கநைஸேஶந் ,ஆரோக்கியம் கனடா மருந்து ஸ்தாபனம் உரிமம் ,ஆரோக்கியம் கனடா ,ஒழுங்குமுறை சேவைகள் வழங்குநர் ,டெட்ரா உயிர் பார்மா ,மருந்து அடையாளம் எண் ,ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு ,